Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Larocca

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|October 5, 2019
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trialSara Bringhen, Mattia D'Agostino, Laura Paris, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Blood|August 13, 2011
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideAlessandra Larocca, Federica Cavallo, Sara Bringhen, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|October 5, 2019
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trialSara Bringhen, Mattia D'Agostino, Laura Paris, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G Richardson, Albert Oriol, Alessandra Larocca, et al.
Haematologica|February 6, 2014
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaMonika Engelhardt, Evangelos Terpos, Martina Kleber, et al.
The Lancet. Oncology|February 15, 2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataAntonio Palumbo, Sara Bringhen, Shaji K Kumar, et al.
Blood|August 13, 2011
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideAlessandra Larocca, Federica Cavallo, Sara Bringhen, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Pageof 10